GSK

1,841

-1.22%↓

GSK

1,841

-1.22%↓

GSK

1,841

-1.22%↓

GSK

1,841

-1.22%↓

GSK

1,841

-1.22%↓

Haleon PLC

Затворен

СекторЗдравеопазване

343.7 1.06

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

341.1

Максимум

343.8

Ключови измерители

By Trading Economics

Приходи

403M

Продажби

2.7B

P/E

Средно за сектора

18.111

49.8

EPS

0.044

Дивидентна доходност

2.09

Марж на печалбата

14.708

Служители

24,535

EBITDA

697M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+27.33% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.09%

2.25%

Следващи печалби

30.07.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

31B

Предишно отваряне

342.64

Предишно затваряне

343.7

Настроения в новините

By Acuity

44%

56%

148 / 347 Класиране в Healthcare

Haleon PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.04.2026 г., 07:48 ч. UTC

Печалби

Sensodyne-Maker Haleon Revenue Rises on Oral Health Growth -- Update

29.04.2026 г., 06:39 ч. UTC

Печалби

Sensodyne-maker Haleon Revenue Rises on Oral Health Growth

25.02.2026 г., 07:55 ч. UTC

Печалби

Panadol Maker Haleon Reports Revenue Slowdown Amid Weak Cold-And-Flu Season

29.04.2026 г., 08:05 ч. UTC

Пазарно говорене
Печалби

Haleon's North America Results Were Encouraging -- Market Talk

29.04.2026 г., 07:46 ч. UTC

Пазарно говорене
Печалби

Haleon's First-Quarter Results Align With Peers -- Market Talk

29.04.2026 г., 06:07 ч. UTC

Печалби

Haleon: 1Q Emerging Markets Revenue Growth 4.3%

29.04.2026 г., 06:06 ч. UTC

Печалби

Haleon: Q1 North America Organic Revenue Growth 1.0%

29.04.2026 г., 06:05 ч. UTC

Печалби

Haleon 1Q Reported Revenue Growth 0.1%

29.04.2026 г., 06:04 ч. UTC

Печалби

Analysts Saw Haleon 1Q Organic Revenue Growth 2.3%

29.04.2026 г., 06:04 ч. UTC

Печалби

Haleon 1Q Organic Revenue Growth 2.2%

29.04.2026 г., 06:04 ч. UTC

Печалби

Haleon 1Q Rev GBP2.86B

29.04.2026 г., 06:04 ч. UTC

Печалби

Haleon Sees High-single Digit Adjusted Operating Profit Growth at Constant Currency in Medium Term

29.04.2026 г., 06:03 ч. UTC

Печалби

Haleon Sees 4% to 6% Organic Rev Growth in Medium Term

29.04.2026 г., 06:03 ч. UTC

Печалби

Haleon Expects a Broadly Neutral Foreign Exchange Translation Impact on Net Rev, Adj Oper Pft

29.04.2026 г., 06:02 ч. UTC

Печалби

Haleon Sees 2026 Adjusted Effective Tax Rate c.24.5%

29.04.2026 г., 06:02 ч. UTC

Печалби

Haleon: Sees 2026 Net Interest GBP255 Million

29.04.2026 г., 06:02 ч. UTC

Печалби

Haleon Sees 2026 High-single Digit Adj Oper Pft Growth at Constant Currency

29.04.2026 г., 06:01 ч. UTC

Печалби

Haleon Sees 2026 Organic Revenue Growth 3% to 5%

25.02.2026 г., 07:18 ч. UTC

Печалби

Haleon 4Q Organic Revenue Growth 2.1%

25.02.2026 г., 07:17 ч. UTC

Печалби

Haleon: GBP500M Allocated to Share Buybacks in 2026

25.02.2026 г., 07:16 ч. UTC

Печалби

Haleon Sees 2026 High Single Digit Adj. Operating Profit Growth at Constant Currency

25.02.2026 г., 07:15 ч. UTC

Печалби

Haleon Sees 2026 Organic Revenue Growth of 3% to 5%

25.02.2026 г., 07:06 ч. UTC

Печалби

Haleon Declares Final Dividend of 4.9p

25.02.2026 г., 07:05 ч. UTC

Печалби

Haleon 2025 Net Pft GBP1.67B

25.02.2026 г., 07:05 ч. UTC

Печалби

Haleon 2025 Pretax Pft GBP2.15B

25.02.2026 г., 07:04 ч. UTC

Печалби

Analysts Saw Haleon 2025 Adj Oper Pft at GBP2.46B

25.02.2026 г., 07:04 ч. UTC

Печалби

Analysts Saw Haleon 2025 Adj Oper Pft Margin at 22.3%

25.02.2026 г., 07:04 ч. UTC

Печалби

Analysts Saw Haleon 2025 Organic Revenue Growth at 3.4%

25.02.2026 г., 07:04 ч. UTC

Печалби

Analysts Saw Haleon 2025 Rev at GBP11.03B

25.02.2026 г., 07:04 ч. UTC

Печалби

Haleon 2025 Adj. Operating Pft Margin 22.9%

Сравнение с други в отрасъла

Ценова промяна

Haleon PLC Прогноза

Ценова цел

By TipRanks

27.33% нагоре

12-месечна прогноза

Среден 426.67 GBX  27.33%

Висок 512 GBX

Нисък 325 GBX

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Haleon PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

9 ratings

7

Купи

1

Задържане

1

Продай

Настроение

By Acuity

148 / 347 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Haleon PLC

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
help-icon Live chat